1. Home
  2. EHI vs CGEN Comparison

EHI vs CGEN Comparison

Compare EHI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global High Income Fund Inc

EHI

Western Asset Global High Income Fund Inc

HOLD

Current Price

$5.85

Market Cap

178.2M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.41

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EHI
CGEN
Founded
N/A
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.2M
191.1M
IPO Year
2003
2001

Fundamental Metrics

Financial Performance
Metric
EHI
CGEN
Price
$5.85
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
84.3K
252.6K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$1.30
52 Week High
$6.70
$3.24

Technical Indicators

Market Signals
Indicator
EHI
CGEN
Relative Strength Index (RSI) 48.01 52.66
Support Level $5.80 $2.20
Resistance Level $5.93 $2.54
Average True Range (ATR) 0.06 0.11
MACD 0.01 0.01
Stochastic Oscillator 58.33 68.18

Price Performance

Historical Comparison
EHI
CGEN

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: